About us
Our mission
We are a clinical-stage biotech company, focused on Individualized Neoantigen Therapeutic Vaccines (INTV), that emerge as breakthrough immunotherapy for early-stage solid tumor patients.
These viral vector-based individualized therapeutic vaccines from Transgene’s myvac® platform aim to unlock the potential of the patient’s immune system to restore the means to fight against the disease. They specifically stimulate and educate the immune system to enable it to recognize and eliminate cancer cells.
INTV myvac® platform
Last update : March 2026.

Alessandro Riva joined Transgene in 2022 as Chairman of the Board of Directors and became Chief Executive Officer in 2023. He brings nearly 30 years’ experience in the Life Sciences industry, in pharmaceutical and biotech companies.
He was CEO of Intima Bioscience which specializes in cell therapies for solid cancers and CEO of Ichnos Sciences. Alessandro Riva was also Executive Vice President (EVP), Global Head of Oncology Therapeutics and Cell & Gene Therapy at Gilead Sciences, where he was instrumental in the acquisition of Kite Pharma and led its integration and growth. He also managed the US and EU approvals of Yescarta, the first approved CAR-T cell therapy for adult patients with diffuse large B cell lymphoma. Prior to Gilead, Alessandro Riva was EVP, Global Head of Oncology Development and Medical Affairs at Novartis Pharmaceuticals. Alessandro Riva currently serves on the Boards of BeOne and Century Therapeutics.
He received his bachelor’s degree in medicine and surgery from the University of Milan and a certificate board in oncology and hematology from the same institution.

Alain Mérieux is Chairman of Institut Mérieux, a family holding company dedicated to medicine and public health worldwide.
In 1963, Alain Mérieux founded bioMérieux, an in vitro diagnostics company. From 1968 to 1994, he was Chairman of Institut Mérieux, which specialized in human and veterinary vaccines, before divesting the vaccine business. In 1994, he created a new bio-industrial pole in the field of diagnostics (bioMérieux), immunotherapy (Transgene and ABL), food safety and nutrition (Mérieux NutriSciences) and health investments (Mérieux Equity Partners).
He is President of Fondation Mérieux, an independent family foundation recognized as being in the public interest, which fights against infectious diseases in developing countries.
Alain Mérieux holds a PhD in Pharmacy. He served as an interna resident in the hospitals of Lyon and attended the PMD at Harvard Business School.

Michel Baguenault de Puchesse has been CEO of Institut Mérieux since January 2020. Prior to this position, Michel held several positions within the Institut Mérieux group: Executive Vice President of Institut Mérieux (2009 – 2011), Corporate Vice President, HR and Communication of bioMérieux (2011 – 2016), Secretary General of bioMérieux, in charge of Human Resources, Communication, Audit – Risks & Compliance, and Protocol (2016 – 2020).
Before joining Institut Mérieux, he was Financial Strategy Advisor at Financière Meeschaert, from 1996 to 2004, and Head of Development at Banque Martin Maurel in Lyon, from 2004 to 2008. Michel Baguenault de Puchesse is a graduate from EM LYON Business School and holds a Law degree. Within the Institut Mérieux Group, Michel Baguenault de Puchesse is a board member of Institut Mérieux, Mérieux NutriSciences, Fondation Christophe & Rodolphe Mérieux, and non-executive President of Mérieux Equity Partners.
Outside the Group, he is board member of CIC Lyonnaise de Banque, Descours & Cabaud SA, Mutuelles AXA, Siparex / Sigefi, Fondation Solidarités by Crédit Agricole. He also joined the supervisory board of Unibel.
Committee: Member of the Compensation Committee

Jean-Luc Bélingard was Chairman and Chief Executive Officer of bioMérieux S.A from 2010 to 2017. He graduated from the Ecole des Hautes Etudes Commerciales (HEC) of Paris (1971) and holds a Master of Business Administration (MBA) from Cornell University, US (1974). Since then, he has held management positions at Merck, Sharp and Dohme (1974-1983), Roche France (“Président du Directoire”, 1983-1990), F. Hoffman-La Roche Ltd. (Member of the Executive Committee, 1990-1998), Roche Diagnostics, Basel (Chief Executive Officer, 1990-1998), bioMérieux-Pierre Fabre (Chief Executive Officer, 1999-2001), Ipsen Group (Chairman and Chief Executive Officer, 2002-2010).
Jean-Luc Bélingard has been a Director of the Company since 2013.
Committee: Chairman of the Strategy Committee

Jean-Yves Blay is Professor of Medical Oncology and has been General Director of the Léon Bérard Center in Lyon since 2014. He holds a PhD obtained in 1994 from the Claude Bernard University in Lyon and has been authorized to supervise research since 1996. He currently leads the LYriCAN project (integrated cancer research) at the French National Cancer Institute. Former president of the European Organization for Research and Treatment of Cancer, Prof. Jean‑Yves Blay is currently director of the NETSARC network accredited by the French National Cancer Institute and president of the French Sarcoma Group. At international level, he is a faculty member of the ESMO (European Society of Medical Oncology) and the SPH (Scientific Panel for Health). He has led the European Commission’s Conticanet network and is currently leading the Eurosarc FP7 project. Author of more than 500 international publications, Prof. Jean-Yves Blay advises various national and international research organizations and institutions. His work has been rewarded by several prizes including that of the French National Academy of Medicine, which he joined as a corresponding member in 2014.
Committee:Chairman of the Clinical Development Committee

Benoît Habert is Executive Vice President and Director of the Marcel Dassault Industrial Group and is a board member of several listed and private companies. He holds an MBA from INSEAD and a Master of Business Law.
Benoît Habert has been a Director of the Company since 2000.
Committees: member of the Compensation Committee and of the Audit Committee

Dorothea Ledergerber currently serves as Multi-Site Head of Drug Product Operations at Siegfried Group and is also a member of the Board of Directors of the CDMO DINAMIQS. A trained pharmacist with a PhD in pharmaceutical sciences, she brings over 25 years of experience in the pharmaceutical and biotechnology industries. She previously held leadership roles at Novartis, where she notably managed industrial operations in Europe and contributed to establishing the company’s first commercial European manufacturing unit for cell and gene therapies. She also served as Chief Technical Officer at Tigen Pharma, a company specializing in autologous cell therapies. Ms. Ledergerber has recognized expertise across the entire pharmaceutical value chain, from research & development through to manufacturing.

Solange Peters is a Swiss medical oncologist and Professor, Head of Oncology, and Chair of Medical Oncology at the Lausanne University Hospital (CHUV). Trained in Switzerland and Italy, she specializes in thoracic oncology, particularly lung and pleural cancers. Her research focuses on biomarker discovery, multimodal strategies for locally advanced non-small cell lung cancer, and cancer immunotherapy.
Beyond her clinical and scientific work, she holds numerous leadership roles, including positions with ETOP, Oncosuisse, the Paris-Saclay Cancer Cluster, and the Swiss Cancer League. She served as President of ESMO from 2020 to 2022, the youngest in its history, and is actively involved in international education initiatives. She also founded ESMO’s “Women for Oncology” committee.
A highly prolific researcher, she has authored over 500 publications and holds editorial roles in leading oncology journals.

Emmanuelle Quilès is a seasoned pharmaceutical industry executive with deep expertise in global strategy, operations, and innovation. Until recently, she served as Worldwide Vice President for Cardiovascular, Metabolism, and Pulmonary Hypertension at Janssen Global Commercial Strategy Organization (Johnson & Johnson) and previously held senior leadership positions at Wyeth, Pfizer, and her own biotech start-up Harmonium. A graduate in biotechnology engineering from Strasbourg University, she has been honored as a Knight of the Legion of Honor for promoting health innovation and women’s leadership. Beyond her corporate roles, she actively contributes to global health innovation initiatives and serves on multiple healthcare advisory boards.

Carol Stuckley brings more than 35 years of experience as a strategic and international financial executive, with proven success leading finance teams and creating shareholder value for healthcare companies. She currently serves as a Board Director and Chairperson of the audit committee of Centessa Pharmaceuticals, plc and previously served on the board of directors of Ipsen (where she chaired the audit committee) and Epizyme, Inc. Carol Stuckley was formerly Chief Financial Officer and Senior Vice President at HPS, which was acquired by TransUnion, Inc. Previously, Carol was Chief Financial Officer, Vice President, Finance at Galderma North America (Nestlé Skin Health S.A.). Carol started her 23-year career at Pfizer Inc., where she held multiple financial roles of increasing responsibility, and was most recently Assistant Treasurer, Vice President, Finance and Corporate Officer of Pfizer Inc. A US citizen, Carol holds a Master of Arts Degree in Economics and an MBA in International Finance from Temple University’s Fox Business School.
Committees: Member of the Audit Committee and of the Compensation Committee

TSGH SAS has been Transgene’s reference shareholder since 1994. This financial holding company is a member of Institut Mérieux Group and is in fine owned by the Mérieux family and by the Christophe and Rodolphe Mérieux Foundation. Philippe Archinard is CEO of TSGH. Sandrine Flory has been TSGH’s permanent representative on Transgene’s Board of Directors since January 2021.
Sandrine Flory has been Chief Financial Officer of Institut Mérieux since 2020. She has spent 18 years at bioMérieux, in various positions in finance. She was CFO for bioMérieux EMEA from 2014 to 2020. Prior to joining bioMérieux, Sandrine Flory spent 9 years at PriceWaterhouseCoopers in France and Australia. She holds a Master’s degree in Finance and Accounting and a MS in Business Valuation and Transmission from the Université Lyon 2 (France).
The financial holding company TSGH has been a Director of the Company since 2002, Sandrine Flory is its representative since 2021.
Committees: Chairwoman of the ESG Comittee, Member of the Audit Committee

John C. Bell, PhD, is an internationally renowned expert in using oncolytic viruses (OVs) to treat cancer. He formed, and continues to lead, the Canadian Oncolytic Virus Consortium, a trans-Canadian, multidisciplinary group developing virus-based cancer therapeutics. He is the Scientific Director of BioCanRx, a Network of Centers of Excellence developing and clinically testing novel immunotherapeutics for the treatment of cancer. He is a co-founder of OV biotechs Jennerex and Turnstone Biologics. John is a senior scientist at the Ottawa Hospital Research Institute (OHRI), a research institution affiliated with the University of Ottawa and the research arm of The Ottawa Hospital. John launched his independent research career in the Department of Biochemistry at McGill University.
His research program has been continuously funded by peer-reviewed grants for over 30 years and he has authored over 400 publications.
He completed his post-doctoral studies at the Medical Research Council in London, England and received his PhD in virology and immunology at McMaster University in Ontario, Canada.

Antoine Italiano , MD, PhD, is a renowned medical oncologist specializing in early drug development and precision medicine. He serves as Head of the Department of Medicine at Institut Bergonié in Bordeaux and leads the Precision Medicine program at Gustave Roussy in Paris. Prof. Italiano has been the Principal Investigator for over 50 Phase I trials and more than 40 Phase II and III trials in the past five years. His research focuses on immuno-oncology, targeted therapies, and translational research, particularly in rare tumors like sarcomas.
He earned his PhD in Molecular Cell Biology in 2008 and completed a postdoctoral fellowship at Memorial Sloan Kettering Cancer Center in New York.
Prof. Italiano is a member of ASCO, AACR, and ESMO, and regularly reviews for top oncology journals. He has authored or co-authored over 500 peer-reviewed publications, including in Nature Medicine, Lancet Oncology, and JAMA Oncology.
He coordinates the CONDOR project, which combines precision medicine and immunotherapy to improve outcomes for metastatic sarcoma patients. Prof. Italiano is also involved in the Multipli study, part of France’s Genomic Medicine 2025 plan, aiming to expand genomic testing in cancer care.
His work has significantly shaped the field of precision oncology, bridging clinical gaps and driving therapeutic innovation.

Ignacio Melero , MD, PhD, is a full professor of immunology at the University of Navarra and co-director of the Department of Immunology and Immunotherapy at the Clínica Universidad de Navarra. He is widely recognized for his pioneering work in cancer immunotherapy, particularly on immunostimulatory monoclonal antibodies and co-stimulation of antitumor immune responses.
He spent three years conducting research at Bristol-Myers Squibb in Seattle, collaborating with leading scientists such as Lieping Chen and Karl Hellström. Since returning to Spain in 1998, he has led a multidisciplinary team at CIMA and the Clínica Universidad de Navarra, focusing on cell-based immunotherapy, gene therapy, and monoclonal antibodies. Prof. Melero has served as principal investigator in over 40 clinical trials in immunotherapy, sponsored by both pharmaceutical companies and academic institutions.
He is a scientific editor for several prestigious journals, including Clinical Cancer Research, Cancer Discovery, and Journal for Immunotherapy of Cancer. He sits on multiple international scientific advisory boards, including those of Institut Curie (Paris), Gustave Roussy, the Netherlands Cancer Institute (NKI), and the Biomedical Research Institute of Granada. In 2023, he was appointed Kidani Professor of Cancer Immuno-Therapeutics at the University of Oxford.
He has published more than 350 scientific articles and supervised over 16 PhD theses, many of which have received awards for excellence. In 2024, he was awarded a prestigious ERC Advanced Grant from the European Union for his research on mRNA-based immunotherapies.

Pedro Romero, MD, is Professor at the Faculty of Biology and Medicine, University of Lausanne, where he has worked since 2003, focusing on tumor immunology and cancer immunotherapy, particularly on the biology and dynamics of cytolytic CD8 T lymphocyte (CTL) responses. He is also Editor-in-Chief of the Journal for ImmunoTherapy of Cancer.
Previously, Pedro researched at the Department of Medical and Molecular Parasitology at New York University School of Medicine before joining the Ludwig Institute for Cancer Research (LICR), Epalinges, Switzerland, in 1989. In 2001, he became division Head of Clinical Onco-Immunology at the LICR in Lausanne.
Pedro holds a number of patents and has coauthored more than 320 original research articles describing his scientific works in peptide-based immunotherapy and T cell responses.
Pedro obtained his MD at the School of Medicine of the National University of Colombia in Bogota.
Transgene complies with the corporate governance recommendations of the MiddleNext Code of Governance for Mid and Small Caps (the Code) (Code de gouvernement d’entreprise des valeurs moyennes et petites de MiddleNext). MiddleNext is an independent society representing midcap public issuers; the Code is largely referred to by small, mid and even large cap firms and accepted by regulators as guidance for best governance practices.
The Board of Directors is currently composed of ten members, elected for renewable three-year terms. Four members of the Board are independent directors as defined in the Code. The Board is chaired by the Chairman and Chief Executive Officer. The Board has adopted a charter of internal regulations that governs the conduct of the Board of Directors and its committees. Detailed information can be found in the Registration Document.
Rules of procedure of the Board of Directors
The Board of Directors is assisted by several committees:
The Audit Committee is composed of three directors of the Board, two of whom are independent. The Vice President Finance is invited to attend each Committee meeting to present the financial situation of the Company. The Audit Committee’s operations are governed by a charter that is reviewed regularly. The committee regularly reports on its work and provides recommendations to the Board of Directors.
Rules of procedure of the audit committee of the Board of Directors
The Compensation Committee is composed of three independent directors two of whom are independent, and is responsible for recommending to the Board of Directors the salaries, bonuses and share-based compensation to executives and key personnel of the Company.
Rules of procedure of the compensation committee of the Board of Directors
The Environmental Social and Governance (ESG) Committee is composed of three directors, one of whom is independent. It was established by a decision of December 15, 2021. The ESG Committee is responsible for preparing discussions for the Board on issues relating to the Company’s social and environmental responsibility and for making recommendations to the Board of Directors in this area.
Rules of procedure of the ESG committee of the Board of Directors (in French)
The Management Committee is a non-statutory body that oversees the Company’s daily operations and ensures, in all managerial aspects, that the Company’s strategy is properly executed in accordance with its objectives.
The Company has established a number of other internal bodies and procedures, for example, for financial controlling, project management and risk management.
Bylaws
Charter on regulated agreements and the procedure for evaluating ordinary-course agreements (In French)







